Treatment of new world cutaneous and mucosal Leishmaniases

Clinics in Dermatology

Volumn 14, Issue 5, 1996, Pages 519-522

  Berman, Jonathan D ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; KETOCONAZOLE; MEGLUMINE ANTIMONATE; PAROMOMYCIN; PENTAMIDINE; STIBOGLUCONATE SODIUM;

ANTIBIOTIC THERAPY; HUMAN; LEISHMANIA BRAZILIENSIS; LEISHMANIA MEXICANA; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SKIN LEISHMANIASIS; TOPICAL DRUG ADMINISTRATION;

EID: 0030248711     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0738-081X(96)00048-X     Document Type: Article

References (16)

1. 1. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306.
2. 2. Navin TR, Arana BA, Arana FE, et al. Placebo controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992;165:528-34.
3. 3. Arana BA, Navin TR, Arana FE, et al. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clin Infect Dis 1994;18:381-4.
4. 4. Ballou WR, McClain JB, Gordon DM, et al. Safety and efficacy of high dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet 1987;2:13-6.
5. 5. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993;16:417-25.
6. 6. Franke ED, Wignall S, Cruz ME, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990;113:934-40.
7. 7. Franke ED, Llanos-Cuentas A, Echevarria J, et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 1994;51:77-82.
8. 8. Gasser RA, Magill AJ, Oster CN. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994;18:83-90.
9. 9. Low-a-chee RM, Rose P, Ridley DS. An outbreak of cutaneous leishmaniasis in Guyana: Epidemiology, clinical and laboratory aspects. Ann Trop Med Parasitol 1983;77: 255-60.
10. 10. Soto J, Buffet P, Grogl M, et al. Successful treatment of Colombian cutaneous leishmaniasis with 4 injections of pentamidine. Am J Trop Med Hyg 1994;50:107-11.
11. 11. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990;89:147-55.
12. 12. Dedet JP, Jamet P, Esterre P. Failure to cure Leishmania braziliensis guyanensis cutaneous leishmaniasis with oral ketoconazole. Trans R Soc Trop Med Hyg 1986;80:176.
13. 13. El-On J, Livshin R, Even-paz Z. Topical treatment of cutaneous leishmaniasis. J Invest Derm 1986;87:284-8.
14. 14. Ben Salah A, Zakraoui H, Zaatour A, et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995;53:162-6.
15. 15. Asilan A, Jalayer T, Whitworth JAG, et al. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995; 53:648-52.
16. 16. Soto J, Hernandez N, Mejia H, et al. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin Infect Dis 1995;20:47-51.